How effective is Kapvay for Attention Deficit Hyperactivity Disorder? (a real world drug study)
Summary:
Overall ratings: 2.6/5 Long term ratings: 3/5
This is a phase IV clinical study of how effective Kapvay (clonidine hydrochloride) is for Attention deficit hyperactivity disorder and for what kind of people. The study is created by eHealthMe from 13 Kapvay users and is updated continuously.
What is Kapvay?
Kapvay has active ingredients of clonidine hydrochloride. It is often used in attention deficit hyperactivity disorder. eHealthMe is studying from 246 Kapvay users. Check the latest studies of Kapvay.
What is Attention deficit hyperactivity disorder?
Attention deficit hyperactivity disorder (a chronic condition including attention difficulty, hyperactivity, and impulsiveness) is found to be associated with 610 drugs and 1,393 conditions by eHealthMe. Check the latest studies of Attention deficit hyperactivity disorder.
13 people are studied for taking Kapvay in Attention deficit hyperactivity disorder
Overall effectiveness (number of people):
Long term (1+ years) effectiveness (number of people):
Kapvay effectiveness for Attention deficit hyperactivity disorder (number of people):
Overall:
- not at all: 0
- somewhat: 7
- moderate: 4
- high: 2
- very high: 0
Long Term:
- not at all: 0
- somewhat: 0
- moderate: 2
- high: 0
- very high: 0
Gender of people who take Kapvay for Attention deficit hyperactivity disorder *:
- female: 38.46 %
- male: 61.54 %
Age of people who take Kapvay for Attention deficit hyperactivity disorder *:
- 0-1: 0.0 %
- 2-9: 38.46 %
- 10-19: 53.85 %
- 20-29: 7.69 %
- 30-39: 0.0 %
- 40-49: 0.0 %
- 50-59: 0.0 %
- 60+: 0.0 %
Who find Kapvay more effective for Attention Deficit Hyperactivity Disorder?
Gender of people who take Kapvay for Attention deficit hyperactivity disorder *:
- female: 0.0 %
- male: 100 %
Age of people who take Kapvay for Attention deficit hyperactivity disorder *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 100 %
- 20-29: 0.0 %
- 30-39: 0.0 %
- 40-49: 0.0 %
- 50-59: 0.0 %
- 60+: 0.0 %
* Approximation only. Some reports may have incomplete information.
Do you take Kapvay?
- You can start a phase IV clinical trial to monitor Kapvay safety and effectiveness.How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Related publications that referenced our studies:
- Coskun M, Adak I, "Excessive and frequent menstrual bleeding with methylphenidate in an adolescent girl with attention-deficit hyperactivity disorder", Journal of clinical psychopharmacology, 2017 Oct .
- Lufi D, Bucherman M, Akita M, Cohen R, Sibani C, "The effect of methylphenidate on speech patterns of children with attention deficit disorder", Journal of Behavioral Health, 2012 Jan .
- Coskun M, Adak I, "Excessive and frequent menstrual bleeding with methylphenidate in an adolescent girl with attention-deficit hyperactivity disorder", Journal of clinical psychopharmacology, 2017 Oct .
- Lufi D, Bucherman M, Akita M, Cohen R, Sibani C, "The effect of methylphenidate on speech patterns of children with attention deficit disorder", Journal of Behavioral Health, 2012 Jan .
Related studies
Alternative drugs to, pros and cons of:
- Kapvay (246 reports)
Treatments, associated drugs and conditions:
- Attention deficit hyperactivity disorder (120,330 reports)
How the study uses the data?
The study is based on clonidine hydrochloride (the active ingredients of Kapvay) and Kapvay (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study neither.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Drug interactions of Depakene and Magnesium Oxide - now
- Could Nuvigil cause Eye Irritation? - 2 seconds ago
- Tyvaso and Blood Glucose Increased for Women aged 50-59 - 4 seconds ago
- Singulair and Fluconazole drug interactions for women aged 20-29 - 6 seconds ago
- Chronic Lymphocytic Leukaemia and drugs of ingredients of diphenhydramine hydrochloride - 10 seconds ago
- Quinapril vs. Midodrine Hydrochloride, side effect and effectiveness comparison - 17 seconds ago
- Could Humira cause Hypotrichosis? - 30 seconds ago
- Back Pain and Sepsis - 33 seconds ago
- Could Robaxin cause Erythema Multiforme? - 41 seconds ago
- Could Haloperidol cause Prinzmetal Angina? - 41 seconds ago